FDA Gives Orphan Drug Status to Potential Multiple Myeloma Immunotherapy
The U.S. Food and Drug Administration (FDA) has granted orphan drug…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
First Patient Dosed in Phase 3 Trial Testing Melflufen Triple Combo
The first participant has been dosed in a Phase…
PT-112 Shows Promise for Heavily Treated Myeloma Patients
Phosplatin Therapeutics‘ investigational medication PT-112 showed promising efficacy…
MMRF Invests in Indapta’s Natural Killer Cell Therapy to Advance Clinical Trials
The Multiple Myeloma Research Foundation (MMRF) is partnering…
FDA Approval Sought for Cilta-cel CAR T-cell Therapy
Janssen and Legend Biotech are seeking U.S. approval for…
FDA Approves Xpovio Triple Combo for Previously Treated Myeloma
The U.S. Food and Drug Administration (FDA) has approved…
